Spinal Muscular Atrophy Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Spinal Muscular Atrophy (SMA) Treatments Market was valued at USD 7.3 billion and is projected to grow at a CAGR of 19.1% from 2024-2032. Key drivers include the expansion of newborn screening programs, leading to earlier diagnoses and increased treatment eligibility. Early diagnosis enhances patient outcomes and boosts demand for neurological medications. Health Union, LLC reports that SMA affects 1 in every 6,000 to 10,000 newborns globally, with Type 1 SMA being the most severe and accounting for over half of all cases. Approximately 25,000 Americans currently live with SMA. Advancements in diagnostic technologies and increased awareness among healthcare providers and patients are anticipated to drive market growth.

The overall spinal muscular atrophy treatment industry is classified based on type, treatment type, route of administration, and region.

The global SMA treatment market is segmented by type into infant SMA, Werdnig-Hoffmann disease, adult SMA, and Kugelberg-Welander disease. The Werdnig-Hoffmann disease segment led the market with USD 2.9 billion in 2023. Mandatory newborn screenings have facilitated earlier detections, enabling prompt treatments that are most effective before significant motor neuron loss. This trend is set to drive market growth. Research and development, along with pharmaceutical collaborations to reduce treatment costs, have broadened patient access, further energizing market growth. Early access or compassionate use programs for SMA Type 1 treatment also bolster market momentum.

By treatment type, the market includes medication, supportive care, and spinal surgery. The medication segment, which includes antisense oligonucleotides, gene therapy, and other drugs, dominated with a 64.2% share in 2023. Innovative drugs like Spinraza (Nusinersen) and Evrysdi (Risdiplam) have transformed SMA treatment by targeting the genetic root and enhancing SMN protein production, driving market growth. The availability of both injectable and oral formulations has increased treatment accessibility, catering to diverse patient needs and preferences, thus fueling market growth.

North America, particularly the U.S., captured a significant 45.6% share of the global SMA treatment market in 2023 and is expected to maintain its dominance. Supportive policies for rare diseases, advanced healthcare facilities, and ongoing clinical trials are key factors driving market growth in the region. Additionally, the presence of leading pharmaceutical companies and increased funding for research and development are further bolstering the market. Rising awareness and early diagnosis of spinal muscular atrophy are also contributing to the expanding treatment landscape.

Product Code: 11091

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360°synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in diagnosis rate of spinal muscular atrophy in infants and children
  - 3.2.1.2 Advancement in gene therapy
  - 3.2.1.3 Growing awareness and screening programs by healthcare providers
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulatory approval for new treatments
  - 3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Werdnig-Hoffmann disease
5.3 Infant SMA
5.4 Kugelberg-Welander disease
5.5 Adult SMA

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Medication
- 6.2.1 Gene therapy
- 6.2.2 Antisense oligonucleotide
- 6.2.3 Other medications
6.3 Supportive care
- 6.3.1 Physical therapy
- 6.3.2 Respiratory support
- 6.3.3 Nutritional support
6.4 Spinal surgery

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Homecare settings
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 American Physical Therapy Association
10.2 Astellas Pharma
10.3 Beijing Jinlan Gene Technology Co., Ltd.
10.4 Biogen Inc.
10.5 Boston's Children Hospital
10.6 Children's Hospital of The King's Daughters
10.7 F. Hoffmann-La Roche Ltd.
10.8 Hanugen Therapeutics
10.9 Nationwide Children's Hospital
10.10 NMD Pharma A/S
10.11 Novartis AG
10.12 Pfizer, Inc.
10.13 Sanofi (Genzyme Corporation)
10.14 Scholar Rock, Inc